{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:22:06Z","timestamp":1785363726570,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health\u00a0Re-\u00a0search\u00a0Program\u00a0of\u00a0Anhui","award":["AHWJ2024Aa20568"],"award-info":[{"award-number":["AHWJ2024Aa20568"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04298-y","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:11:06Z","timestamp":1769490666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement contributes to ICI-triggered sialadenitis and predicts ICI efficacy"],"prefix":"10.1007","volume":"75","author":[{"given":"Xiangqian","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"2","key":"4298_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","volume":"78","author":"C Sposito","year":"2023","unstructured":"Sposito C, Ratti F, Cucchetti A, Ardito F, Ruzzenente A, Di Sandro S et al (2023) Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol 78(2):356\u2013363","journal-title":"J Hepatol"},{"issue":"10","key":"4298_CR2","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C et al (2020) Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 130(10):5380\u20135396","journal-title":"J Clin Invest"},{"issue":"7","key":"4298_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/gutjnl-2021-324109","volume":"71","author":"LI Ruffolo","year":"2022","unstructured":"Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA et al (2022) GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 71(7):1386\u20131398","journal-title":"Gut"},{"issue":"5","key":"4298_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP et al (2021) Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov 11(5):1248\u20131267","journal-title":"Cancer Discov"},{"issue":"13","key":"4298_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857269","volume":"18","author":"Y Nagafuchi","year":"2022","unstructured":"Nagafuchi Y, Yanaoka H, Fujio K (2022) Lessons from transcriptome analysis of autoimmune diseases. Front Immunol 18(13):857269","journal-title":"Front Immunol"},{"issue":"14","key":"4298_CR6","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"24","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks. Front Immunol 24(14):1212476","journal-title":"Front Immunol"},{"issue":"1","key":"4298_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"4298_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473\u2013486","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"4298_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","volume":"30","author":"R Poto","year":"2022","unstructured":"Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG et al (2022) Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol 30(13):804597","journal-title":"Front Immunol"},{"issue":"2020","key":"4298_CR10","doi-asserted-by":"publisher","first-page":"2640273","DOI":"10.1155\/2020\/2640273","volume":"4","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Zeng L, Shen Q, Zhou Z, Mao Z, Wang Q et al (2020) Diagnosis and treatment of rheumatic adverse events related to immune checkpoint inhibitors. J Immunol Res 4(2020):2640273","journal-title":"J Immunol Res"},{"issue":"1","key":"4298_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76(1):43\u201350","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"4298_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2169\/internalmedicine.4701-20","volume":"59","author":"T Higashi","year":"2020","unstructured":"Higashi T, Miyamoto H, Yoshida R, Furuta Y, Nagaoka K, Naoe H et al (2020) Sj\u00f6gren\u2019s syndrome as an immune-related adverse event of Nivolumab treatment for gastric cancer. Intern Med 59(20):2499\u20132504","journal-title":"Intern Med"},{"issue":"2","key":"4298_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.rdc.2024.02.004","volume":"50","author":"S Bitoun","year":"2024","unstructured":"Bitoun S, Rousseau A, Gosset M, Belkhir R, Lazure T, Mariette X et al (2024) Immune checkpoint inhibitor-induced sicca syndrome. Rheum Dis Clin North Am 50(2):291\u2013300","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"4298_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.drudis.2014.05.017","volume":"19","author":"E Corsiero","year":"2014","unstructured":"Corsiero E, Pitzalis C, Bombardieri M (2014) Peripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis. Drug Discov Today 19(8):1161\u20131165","journal-title":"Drug Discov Today"},{"issue":"7","key":"4298_CR15","first-page":"203","volume":"13","author":"EY Kim","year":"2016","unstructured":"Kim EY, Durai M, Mia Y, Kim HR, Moudgil KD (2016) Modulation of adjuvant arthritis by cellular and humoral immunity to Hsp65. Front Immunol 13(7):203","journal-title":"Front Immunol"},{"issue":"1","key":"4298_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/imr.13238","volume":"318","author":"KM Dhodapkar","year":"2023","unstructured":"Dhodapkar KM, Duffy A, Dhodapkar MV (2023) Role of B cells in immune-related adverse events following checkpoint blockade. Immunol Rev 318(1):89\u201395","journal-title":"Immunol Rev"},{"issue":"2","key":"4298_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1172\/JCI99036","volume":"128","author":"SM Liudahl","year":"2018","unstructured":"Liudahl SM, Coussens LM (2018) B cells as biomarkers: predicting immune checkpoint therapy adverse events. J Clin Invest 128(2):577\u2013579","journal-title":"J Clin Invest"},{"issue":"7791","key":"4298_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW, Sun CM, Calderaro J et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556\u2013560","journal-title":"Nature"},{"issue":"5","key":"4298_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S (2019) B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179(5):1191-1206.e21","journal-title":"Cell"},{"issue":"2","key":"4298_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK et al (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128(2):715\u2013720","journal-title":"J Clin Invest"},{"issue":"Suppl 7","key":"4298_CR21","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann SC, Pisetsky DS (2019) Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford) 58(Suppl 7):vii59\u2013vii67","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4298_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","volume":"39","author":"D Cornec","year":"2012","unstructured":"Cornec D, Devauchelle-Pensec V, Tob\u00f3n GJ, Pers JO, Jousse-Joulin S, Saraux A (2012) B cells in Sj\u00f6gren\u2019s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 39(3):161\u2013167","journal-title":"J Autoimmun"},{"key":"4298_CR23","first-page":"214","volume":"93","author":"B Ghebrehiwet","year":"1993","unstructured":"Ghebrehiwet B, Galanakis DK (1993) C1q inhibitor (chondroitin-4-sulfate proteoglycan): structure and function. Behring Inst Mitt 93:214\u2013223","journal-title":"Behring Inst Mitt"},{"issue":"16","key":"4298_CR24","doi-asserted-by":"publisher","first-page":"1519082","DOI":"10.3389\/fphar.2025.1519082","volume":"31","author":"T Yan","year":"2025","unstructured":"Yan T, Long M, Liu C, Zhang J, Wei X, Li F, Liao D (2025) Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients. Front Pharmacol 31(16):1519082","journal-title":"Front Pharmacol"},{"issue":"9","key":"4298_CR25","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384\u20133391","journal-title":"J Clin Invest"},{"issue":"1","key":"4298_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imr.13258","volume":"318","author":"F Berner","year":"2023","unstructured":"Berner F, Flatz L (2023) Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: a focus on autoimmune skin toxicity and pneumonitis. Immunol Rev 318(1):37\u201350","journal-title":"Immunol Rev"},{"issue":"7","key":"4298_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher K, Johnson DB (2024) Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer 12(7):e008591","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4298_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","volume":"15","author":"I Les","year":"2023","unstructured":"Les I, Mart\u00ednez M, P\u00e9rez-Francisco I, Cabero M, Teijeira L, Arrazubi V et al (2023) Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel) 15(5):1629","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4298_CR29","doi-asserted-by":"publisher","first-page":"2188719","DOI":"10.1080\/2162402X.2023.2188719","volume":"12","author":"BC Park","year":"2023","unstructured":"Park BC, Narayanan S, Gavraldis A, Ye F, Fan R, Sullivan RJ et al (2023) Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations. Oncoimmunology 12(1):2188719","journal-title":"Oncoimmunology"},{"issue":"8","key":"4298_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","volume":"23","author":"RS Herati","year":"2022","unstructured":"Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA et al (2022) PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat Immunol 23(8):1183\u20131192","journal-title":"Nat Immunol"},{"issue":"18","key":"4298_CR31","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1158\/0008-5472.CAN-16-0342","volume":"77","author":"A Herrmann","year":"2017","unstructured":"Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H et al (2017) CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res 77(18):5118\u20135128","journal-title":"Cancer Res"},{"key":"4298_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108735","volume":"108","author":"H Liu","year":"2022","unstructured":"Liu H, Wu J, Xu X, Wang H, Zhang C, Yin S et al (2022) Peritumoral TIGIT+CD20+ b cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer. Int Immunopharmacol 108:108735","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"4298_CR33","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","volume":"71","author":"PB Olkhanud","year":"2011","unstructured":"Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K et al (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4\u207a T cells to T-regulatory cells. Cancer Res 71(10):3505\u20133515","journal-title":"Cancer Res"},{"key":"4298_CR34","doi-asserted-by":"publisher","unstructured":"Bod L, Kye YC, Shi J, Torlai Triglia E, Schnell A, Fessler J, Ostrowski SM, Von-Franque MY, Kuchroo JR, Barilla RM, Zaghouani S, Christian E, Delorey TM, Mohib K, Xiao S, Slingerland N, Giuliano CJ, Ashenberg O, Li Z, Rothstein DM, Fisher DE, Rozenblatt-Rosen O, Sharpe AH, Quintana FJ, Apetoh L, Regev A, Kuchroo VK (2023) B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature 619(7969):348-356. https:\/\/doi.org\/10.1038\/s41586-023-06231-0","DOI":"10.1038\/s41586-023-06231-0"},{"issue":"13","key":"4298_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991433","volume":"11","author":"J Taylor","year":"2023","unstructured":"Taylor J, Gandhi A, Gray E, Zaenker P (2023) Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front Immunol 11(13):991433","journal-title":"Front Immunol"},{"key":"4298_CR36","doi-asserted-by":"publisher","unstructured":"Xiangqian Guan, Yuyan Lu, Chuanzheng wang et al (2024) CD61+LDNs drive cancer metastasis by upregulating CCDC25 expression via DNA-TLR9-NF-kB axis in HCC. PREPRINT (Version 1) available at Research Square [https:\/\/doi.org\/10.21203\/rs.3.rs-3868978\/v1]","DOI":"10.21203\/rs.3.rs-3868978\/v1"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04298-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04298-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04298-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:11:07Z","timestamp":1769490667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04298-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4298"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04298-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was performed according to the declaration of relevant guidelines and regulations and was approved by the ethics committee of First Affiliated Hospital of University of Science and Technology of China (No.2025-RE-210\/2024-RE-318). This study has obtained the written informed consent forms provided by all participants prior to isolation and use of the samples. No.2025-RE-210 belonged to the collection of human glandulae labiales and circulation blood. Animal studies were approved by the Animal Care Committee of First Affiliated Hospital of University of Science and Technology of China (2024-RE-318). Registry and the Registration No. of the study\/trial: \u201cComplement contributes to ICI-triggered sialadenitis and predicts ICI efficacy\u201d, No.2025-RE-210.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"50"}}